Skye Bioscience, Inc. (SKYE) Free cash flow 2016–2025
Skye Bioscience, Inc. (SKYE) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$43.1MFY2025 · since FY2016: -$3.6M → -$43.1M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$43.1M | -60.5% |
| FY2024 | -$26.8M | -92.2% |
| FY2023 | -$14.0M | -9.3% |
| FY2022 | -$12.8M | -94.5% |
| FY2021 | -$6.6M | -8.3% |
| FY2020 | -$6.1M | — |
| FY2018 | -$3.9M | -17.8% |
| FY2017 | -$3.4M | +6.0% |
| FY2016 | -$3.6M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More SKYE financial trends
SKYE RevenueSKYE Net incomeSKYE Net marginSKYE Gross profitSKYE Gross marginSKYE Operating incomeSKYE Operating marginSKYE Operating cash flowSKYE Capital expendituresSKYE Return on equitySKYE Stock buybacksSKYE Dividends paidSKYE Total assetsSKYE Total liabilitiesSKYE Shareholders’ equitySKYE overview →